Vital Therapies, Inc. (VTL) Set to Announce Earnings on Monday
Vital Therapies, Inc. (NASDAQ:VTL) is set to release its earnings data after the market closes on Monday, July 31st. Analysts expect Vital Therapies to post earnings of ($0.35) per share for the quarter.
Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings data on Tuesday, May 9th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.02. During the same period in the prior year, the business earned ($0.31) EPS. On average, analysts expect Vital Therapies to post $-1.77 EPS for the current fiscal year and $-1.37 EPS for the next fiscal year.
Shares of Vital Therapies, Inc. (NASDAQ:VTL) opened at 2.65 on Monday. Vital Therapies, Inc. has a 12 month low of $2.25 and a 12 month high of $6.68. The firm’s market cap is $111.85 million. The stock’s 50 day moving average is $2.94 and its 200 day moving average is $3.84.
TRADEMARK VIOLATION NOTICE: “Vital Therapies, Inc. (VTL) Set to Announce Earnings on Monday” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/24/vital-therapies-inc-vtl-set-to-announce-earnings-on-monday.html.
Several research firms have recently issued reports on VTL. Zacks Investment Research raised Vital Therapies from a “sell” rating to a “hold” rating in a research note on Thursday, April 6th. ValuEngine cut Vital Therapies from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Raymond James Financial, Inc. began coverage on Vital Therapies in a research note on Thursday, May 18th. They set an “outperform” rating and a $6.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. Vital Therapies has an average rating of “Hold” and an average target price of $8.00.
In other news, Director Muneer A. Satter purchased 10,000 shares of Vital Therapies stock in a transaction that occurred on Tuesday, June 6th. The shares were bought at an average cost of $3.19 per share, with a total value of $31,900.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Muneer A. Satter purchased 30,000 shares of Vital Therapies stock in a transaction that occurred on Monday, June 12th. The stock was purchased at an average cost of $3.11 per share, for a total transaction of $93,300.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 108,400 shares of company stock worth $338,153. 29.88% of the stock is owned by insiders.
About Vital Therapies
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.